Phathom Pharmaceuticals Plans Financial Results Presentation
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT), a pioneering biopharmaceutical company at the forefront of innovative treatments for gastrointestinal diseases, is gearing up to unveil its financial performance for the third quarter of 2024. A highly anticipated live webcast will take place to discuss these results and share insights into ongoing business developments.
The Live Webcast Event
The webcast is scheduled for Thursday, November 7, 2024, at 8:30 am ET. This event will serve as an opportunity for investors and analysts to gain valuable updates and understand the latest strategic initiatives taken by Phathom Pharmaceuticals.
Accessing the Webcast
Interested participants can access the live webcast through the Events & Presentations section on the Phathom Pharmaceuticals website. After the event concludes, a recording will be made available for viewing for up to 90 days, ensuring that stakeholders can catch up on any important information they may have missed.
About Phathom Pharmaceuticals
Phathom Pharmaceuticals stands out with its commitment to developing cutting-edge treatments that address chronic gastrointestinal conditions. The company has made strides with its product, vonoprazan, which is distinguished as a first-in-class potassium-competitive acid blocker (PCAB). This innovative drug is already making waves in the marketplace, particularly with its use in treating conditions like heartburn and Erosive GERD.
Innovative Solutions for Gastrointestinal Disorders
Vonoprazan, marketed under the brand name VOQUEZNA, is specifically designed to provide relief from heartburn linked to Non-Erosive GERD, as well as to facilitate the healing of Erosive GERD in adults. Additionally, the product line includes VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, which combine vonoprazan with antibiotics for effective treatment of H. pylori infections in adults.
Commitment to Patients and Advancement
The ongoing development of these therapies underscores Phathom's commitment to improving patient outcomes and advancing treatment options available in the market. By focusing on innovative approaches, Phathom Pharmaceuticals is poised to play a significant role in the biopharmaceutical landscape, particularly concerning gastrointestinal health.
Media and Investor Relations Contact
For media inquiries or further information, Nick Benedetto can be reached at 1-877-742-8466. Investors looking for more details about the company's performance are encouraged to contact Eric Sciorilli at the same number. Phathom is dedicated to maintaining open lines of communication with stakeholders and the public.
Frequently Asked Questions
What is Phathom Pharmaceuticals known for?
Phathom Pharmaceuticals is recognized for developing innovative treatments for gastrointestinal diseases, particularly through its flagship product, vonoprazan.
When will the financial results be presented?
The financial results for Q3 2024 will be presented on November 7, 2024, at 8:30 am ET during a live webcast.
How can I access the webcast of the financial results?
The webcast will be available on Phathom Pharmaceuticals' website in the Events & Presentations section and will be accessible for 90 days after the event.
What products does Phathom Pharmaceuticals offer?
Phathom Pharmaceuticals offers a range of products, including VOQUEZNA, VOQUEZNA DUAL PAK, and VOQUEZNA TRIPLE PAK, targeting various gastrointestinal conditions.
How does Phathom engage with investors?
Phathom maintains open communication with investors through ongoing updates and dedicated contact points for inquiries and information requests.
